Reuters Reports Merck & Co No Longer Plans To Occupy The Belgrove House Site At King's Cross; Intends To Vacate Laboratories Occupied At The LBIC, The Francis Crick Institute By End Of 2025, Impacting Approximately 125 Positions; Increasing Overal...
Merck & Co., Inc.
MRK
|
99.72
|
-1.16%
|
Reuters Reports Merck & Co No Longer Plans To Occupy The Belgrove House Site At King's Cross; Intends To Vacate Laboratories Occupied At The LBIC, The Francis Crick Institute By End Of 2025, Impacting Approximately 125 Positions; Increasing Overall R&D Investment, With Particular Emphasis On Repositioning Discovery Activities And Related Capabilities In U.S.; Challenges Include "UK Not Making Meaningful Progress Towards Addressing The Lack Of Investment In The Life Science Industry"